Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 4/20 | 0.33 |
| ▸ | THRA | P10827 | 3/20 | 0.33 |
| ▸ | DNM2 | P50570 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902921 | 1.00 | DNM1 (0.60) | DNM1TSHRALDH1A1TDP1THRB | |
| SCHEMBL7184171 | 1.00 | DNM1 (0.60) | DNM1TSHRALDH1A1TDP1THRB | |
| Dymanthine SCHEMBL7895663 | 0.94 | DNM1 (0.62) | DNM1TSHRALDH1A1TDP1THRB | |
| SCHEMBL6549792 | 0.94 | DNM1 (0.62) | DNM1TSHRALDH1A1TDP1THRB | |
| SCHEMBL6036516 | 0.94 | DNM1 (0.62) | DNM1TSHRALDH1A1TDP1THRB | |
| SCHEMBL7903579 | 0.94 | DNM1 (0.62) | DNM1TSHRALDH1A1TDP1THRB | |
| SCHEMBL8508979 | 0.94 | DNM1 (0.62) | DNM1TSHRALDH1A1TDP1THRB | |
| SCHEMBL7904761 | 0.94 | DNM1 (0.62) | DNM1TSHRALDH1A1TDP1THRB | |
| SCHEMBL29137867 | 0.89 | DNM1 (0.75) | DNM1TSHRALDH1A1TDP1THRB | |
| SCHEMBL7903172 | 0.89 | DNM1 (0.75) | DNM1TSHRALDH1A1THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125547-B2 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-6610283-B1 | Method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a | GENZYME CORPORATION | 2003-08-26 | — | — | US | disclosed |
| EP-1094801-A2 | POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-1999022743-A1 | POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1998029107-A2 | POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | DNM1 3469/4885TSHR 4388/4885ALDH1A1 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.